Cognitive outcomes after fetal exposure to carbamazepine, lamotrigine, valproate or levetiracetam monotherapy: Data from the EURAP neurocognitive extension protocol
Epilepsy & Behavior · 2024
DOI: 10.1016/j.yebeh.2024.110024 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Epilepsy & Behavior, 2024. Verfasst von Susanna Stjerna und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuropsychology, HUS Neurocenter, and BABA Centre, Paediatric Research Centre, Children's Hospital, University of Helsinki and Helsinki…. Hauptthemen laut MEDLINE: Anticonvulsants, Carbamazepine, Epilepsy, Lamotrigine. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UCB, Abbott, GlaxoSmithKline Inc.
Abstract (Originalsprache)
PURPOSE: Prenatal exposure to antiseizure medications (ASMs) has been associated with an increased risk of major malformations and neurodevelopmental disorders, with the latter being mainly associated with valproate (VPA). Our aim was to compare neurocognitive outcome at age 6-7 years in children exposed prenatally to lamotrigine (LTG), carbamazepine (CBZ), valproate (VPA) or levetiracetam (LEV) monotherapy. METHODS: Eligible mother-child pairs were identified from the observational prospective multinational EURAP cohort study. Assessor-blinded testing was conducted at age 6-7 years using WISC-III and NEPSY-II. Verbal IQ (VIQ), performance IQ (PIQ), full scale IQ (FSIQ) and performance in neuropsychological tasks were compared across ASM groups by ANOVA. Scores were adjusted for maternal IQ, paternal education, maternal epilepsy type and child sex. RESULTS: Of 169 children enrolled in the study, 162 (LTG n = 80, CBZ n = 37, VPA n = 27, LEV n = 18) had sufficient data from WISC-III, NEPSY-II or both, and were included in the analyses. Observed (unadjusted) PIQ and FSIQ did not differ across exposure groups, but a difference was identified for VIQ (P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuropsychology, HUS Neurocenter, and BABA Centre, Paediatric Research Centre, Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Electronic address: susanna.s…
- Kenter Jeugdhulp, Amstelland, Amstelveen, the Netherlands.
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
- Department of Medicine (Austin Health), The University of Melbourne (Austin Health), Melbourne, Victoria, Australia; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia.
- Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
- Department of Neurology, Belfast Health and Social Care Trust, Belfast, United Kingdom.
Förderung
- UCB
- Abbott
- GlaxoSmithKline Inc
- Sanofi Aventis GmbH
Zitieren
APA
Stjerna, S., Huber-Mollema, Y., Tomson, T., Perucca, E., Battino, D., Craig, J., Sabers, A., Thomas, S., Vajda, F., & Gaily, E. (2024). Cognitive outcomes after fetal exposure to carbamazepine, lamotrigine, valproate or levetiracetam monotherapy: Data from the EURAP neurocognitive extension protocol. Epilepsy & Behavior. https://doi.org/10.1016/j.yebeh.2024.110024
Vancouver
Stjerna S, Huber-Mollema Y, Tomson T, Perucca E, Battino D, Craig J, et al. Cognitive outcomes after fetal exposure to carbamazepine, lamotrigine, valproate or levetiracetam monotherapy: Data from the EURAP neurocognitive extension protocol. Epilepsy & Behavior. 2024. doi:10.1016/j.yebeh.2024.110024
BibTeX
@article{Stjerna2024,
author = {Stjerna, Susanna and Huber-Mollema, Yfke and Tomson, Torbjörn and Perucca, Emilio and Battino, Dina and Craig, John and Sabers, Anne and Thomas, Sanjeev and Vajda, Frank and Gaily, Eija},
title = {Cognitive outcomes after fetal exposure to carbamazepine, lamotrigine, valproate or levetiracetam monotherapy: Data from the EURAP neurocognitive extension protocol},
journal = {Epilepsy & Behavior},
year = {2024},
doi = {10.1016/j.yebeh.2024.110024}
}
EUVIMED